Macrophage-Related Gene Signatures for Predicting Prognosis and Immunotherapy of Lung Adenocarcinoma by Machine Learning and Bioinformatics

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Testa U, Castelli G, Pelosi E. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers. 2018;10:1.
   Web of Science ®Google Scholar
• Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007;57:253–260. doi:10.1016/j.lungcan.2007.03.012
   PubMed Web of Science ®Google Scholar
• Chang JT, Lee YM, Huang RS. The impact of the cancer genome atlas on lung cancer. Transl Res. 2015;166:568–585. doi:10.1016/j.trsl.2015.08.001
   PubMed Web of Science ®Google Scholar
• Travis, William D, Brambilla, Elisabeth, Noguchi, Masayuki et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Zhang Y, Du H, Li Y, Yuan Y, Chen B, Sun S. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma. Cancer Sci. 2020;111:637–646. doi:10.1111/cas.14226
   PubMed Web of Science ®Google Scholar
• He D, Wang D, Lu P, et al. Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene. 2021;40:355–368. doi:10.1038/s41388-020-01528-0
   PubMed Web of Science ®Google Scholar
• Zhao J, Guo C, Ma Z, Liu H, Yang C, Li S. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: a comprehensive analysis based on TCGA and GEO databases. Lung Cancer. 2020;149:90–96. doi:10.1016/j.lungcan.2020.09.014
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Choi H, Na KJ. Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: clinical and prognostic implications. Theranostics. 2018;8(7):1956–1965. doi:10.7150/thno.23767
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Vano Y, et al. Tumor-infiltrating and peripheral blood T cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23:4416–4428. doi:10.1158/1078-0432.CCR-16-2848
   PubMed Web of Science ®Google Scholar
• Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88–110. doi:10.1038/nrgastro.2015.200
   PubMed Web of Science ®Google Scholar
• Wang T, Dai L, Shen S, et al. Comprehensive molecular analyses of a macrophage-related gene signature with regard to prognosis, immune features, and biomarkers for immunotherapy in hepatocellular carcinoma based on WGCNA and the LASSO algorithm. Front Immunol. 2022;13:843408. doi:10.3389/fimmu.2022.843408
   PubMed Web of Science ®Google Scholar
• Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541–566. doi:10.1146/annurev-physiol-022516-034339
   PubMed Web of Science ®Google Scholar
• Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154:186–195. doi:10.1111/imm.12910
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–896. doi:10.1038/ni.1937
   PubMed Web of Science ®Google Scholar
• Wildes TJ, Dyson KA, Francis C, et al. Immune escape after adoptive T-cell therapy for malignant gliomas. Clin Cancer Res. 2020;26(21):5689–5700. doi:10.1158/1078-0432.CCR-20-1065
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51. doi:10.1016/j.cell.2010.03.014
   PubMed Web of Science ®Google Scholar
• Coates PJ, Rundle JK, Lorimore SA, Wright EG. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res. 2008;68(2):450–456. doi:10.1158/0008-5472.CAN-07-3050
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveals genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2016;18:248–262. doi:10.1016/j.celrep.2016.12.019
   Web of Science ®Google Scholar
• Liu J, Shen H, Gu W, et al. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma. Front Immunol. 2022;13:960738. doi:10.3389/fimmu.2022.960738
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang K, Zhi Y, et al. Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. Clin Transl Med. 2021;11(9):e478. doi:10.1002/ctm2.478
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Jurisic V, Obradovic J, Pavlovic S, Djordjevic N. Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation. Anal Cell Pathol. 2018;2018:6192187. doi:10.1155/2018/6192187
   Web of Science ®Google Scholar
• Rafei H, El-Bahesh E, Finianos A, Nassereddine S, Tabbara I. Immune-based therapies for non-small cell lung cancer. Anticancer Res. 2017;37:377–387. doi:10.21873/anticanres.11330
   PubMed Web of Science ®Google Scholar
• Li F, Huang Q, Luster TA, et al. In vivo epigenetic CRISPR screen identifies asf1a as an immunotherapeutic target in kras-mutant lung adenocarcinoma. Cancer Discov. 2020;10:270–287. doi:10.1158/2159-8290.CD-19-0780
   PubMed Web of Science ®Google Scholar
• Salman RP, Vamsidhar V, Benjamin GN, Kwok-Kin W. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637–655. doi:10.1038/s41571-022-00671-9
   PubMed Web of Science ®Google Scholar
• Boesch M, Baty F, Rumpold H, Sopper S, Wolf D, Brutsche MH. Fibroblasts in cancer: defining target structures for therapeutic intervention. Biochim Biophys Acta Rev Cancer. 2019;1872:111–121. doi:10.1016/j.bbcan.2019.06.003
   PubMed Web of Science ®Google Scholar
• Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154:3–20. doi:10.1111/imm.12888
   PubMed Web of Science ®Google Scholar
• Shao Y, Saredy J, Yang WY, et al. Vascular endothelial cells and innate immunity. Arterioscler Thromb Vasc Biol. 2020;40:e138–e152. doi:10.1161/ATVBAHA.120.314330
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31. doi:10.1186/s13045-018-0578-4
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17:129. doi:10.1186/s12943-018-0864-3
   PubMed Web of Science ®Google Scholar
• Xu F, Huang X, Li Y, Chen Y, Lin L. m(6)A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids. 2021;24:780–791. doi:10.1016/j.omtn.2021.04.003
   PubMedGoogle Scholar
• Czerwinska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. J Biomed Sci. 2017;24:63. doi:10.1186/s12929-017-0374-4
   PubMed Web of Science ®Google Scholar
• Zhang RY, Liu ZK, Wei D, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. Signal Transduct Target Ther. 2021;6:64. doi:10.1038/s41392-020-00432-z
   PubMed Web of Science ®Google Scholar
• Wei C, Cheng J, Zhou B, et al. Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein. Sci Rep. 2016;6:29822. doi:10.1038/srep29822
   PubMed Web of Science ®Google Scholar
• Li F, Wang Z, Lu G. TRIM28 promotes cervical cancer growth through the mTOR signaling pathway. Oncol Rep. 2018;39:1860–1866. doi:10.3892/or.2018.6235
   PubMed Web of Science ®Google Scholar